Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -50.49M | -53.52M | -52.80M | -54.81M | -41.81M |
| Total Depreciation and Amortization | 79.00K | 81.00K | 80.00K | 81.00K | 85.00K |
| Total Amortization of Deferred Charges | 377.00K | 356.00K | 333.00K | 322.00K | 217.00K |
| Total Other Non-Cash Items | 4.50M | 6.06M | 5.58M | 4.62M | 4.89M |
| Change in Net Operating Assets | 7.95M | 8.82M | -5.55M | 11.15M | 5.43M |
| Cash from Operations | -37.58M | -38.21M | -52.35M | -38.64M | -31.19M |
| Capital Expenditure | 0.00 | -20.00K | -- | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -20.00K | -- | 0.00 | 0.00 |
| Total Debt Issued | -- | -- | -- | 0.00 | 30.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 250.00K | 24.92M | 50.00K | 48.00K |
| Repurchase of Common Stock | 0.00 | 0.00 | -27.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -739.00K | 0.00 | 0.00 |
| Cash from Financing | 0.00 | 250.00K | 24.15M | 50.00K | 30.05M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -37.58M | -37.98M | -28.20M | -38.59M | -1.14M |